Atlantic Equities Maintains Neutral on Biogen, Lowers Price Target to $275
Portfolio Pulse from richadhand@benzinga.com
Atlantic Equities analyst Steve Chesney maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $282 to $275.

August 08, 2023 | 8:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered from $282 to $275 by Atlantic Equities, which maintains a Neutral rating on the stock.
The lowering of the price target by Atlantic Equities could potentially create a negative sentiment among investors. However, the maintained Neutral rating indicates that the analyst does not expect significant changes in the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100